股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 中康控股有限公司 | | | | 呈交日期: | 2026年2月5日 | | | I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02361 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000, ...

中康控股(02361)发布公告，据董事会深知、尽悉及确信，于本公告日期，公司的公众持股量约为 16.45%，已低于上市规则第8.08(1)(a)条所规定公众至少须持有公司已发行股份总数的25%。 ...

智通财经APP讯，中康控股(02361)发布公告，据董事会深知、尽悉及确信，于本公告日期，公司的公众 持股量约为16.45%，已低于上市规则第8.08(1)(a)条所规定公众至少须持有公司已发行股份总数的25%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 下表載列於本公告日期本公司的股權架構： | | | 佔本公司 | | --- | --- | --- | | | | 已發行 | | | | 股本總額的 | | 股東 | 股份數目 | 概約百分比 | | 盈連有限公司 | 181,237,500 | 40.12% | | WLF Investment Holdings Limited | 20,250,000 | 4.48% | | Rikan Industry Investment Limited Partnership | 67,500,000 | 14.94% | | Montesy Capital Holding Ltd | 68,512,500 | 15.17% | | （附註） 富途信託有限公司－未授予股份獎勵 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 2026年1月15日舉行的股東特別大會投票表決結果 董事會欣然宣佈，於2026年1月15日舉行的股東特別大會上提呈的決議案已以投票表決 方式正式通過。 本公司的香港股份過戶登記處寶德隆證券登記有限公司已獲委任為監票人，負責股東特別 大會上的點票工作。於股東特別大會上提呈的決議案的投票結果如下： | 特別決議案 | 股份數目(%) | | | --- | --- | --- | | | 贊成 | 反對 | | 1. 通過（無論有否修訂）下列決議案： | 349,104,250 | 0 | | | (100.0000%) | (0.0000%) | | 「動議待開曼群島公司註冊處處長批准及以此作 | | | | 為條件，自本公司新英文名稱及雙重外文名稱記 | | | | 入開曼群 ...

Core Viewpoint - Zhongkang Holdings (02361) is upgrading its strategy from a "provider of intelligent solutions in the life sciences" to an "AI technology service company based on health industry data elements and ecological resources" [1] Group 1: Strategic Upgrade - The company is transitioning from "data technology services" to "AI decision-making and intelligent services," leveraging a comprehensive capability of "data + model + scenario + ecology" [1] - The dual-domain large model includes: (1) Zhuomuniao (medical large model), which is trained on medical literature, case histories, and pharmaceutical knowledge graphs, evaluated by medical experts for enhanced professionalism and accuracy; (2) Tiangong No. 1 (decision-making large model), which integrates diverse market data and industry logic with medical knowledge to create actionable marketing strategies and resource allocation plans [1] Group 2: Data Resources and Industry Insights - The company possesses a diverse range of health industry data resources covering medical institutions, health check-up centers, and pharmacies, establishing a comprehensive data system from hospitals to outpatient services, online to offline, and prevention to treatment [1] - With 18 years of industry know-how, the company decodes the business logic behind the data, dismantling complex business scenarios to assist in key decision-making [1] Group 3: AI Service System and Team Collaboration - The company has built a complete AI service system from foundational to front-end applications, capable of meeting diverse needs from SMEs to large corporate clients [2] - The team and partners combine top-tier AI technology with extensive pharmaceutical experience, ensuring the integration of technology with medical scenarios to create quantifiable value [2] - Under the new strategic guidance, Zhongkang will leverage its core capabilities to drive AI implementation across four key scenarios: health industry marketing, medical services, pharmacies, and health management [2] Group 4: Future Development - The company will adhere to its established development strategy, building an efficient collaborative ecosystem of health industry intelligent entities based on industrial-level data, continuously leading the industry into a new era of intelligence [3]

Core Viewpoint - The company is transitioning from a "provider of intelligent solutions in the life sciences" to an "AI technology service company based on health industry data elements and ecological resources" [1] Group 1: Strategic Upgrade - The strategic upgrade from "data technology services" to "AI decision-making and intelligent services" is based on a comprehensive capability of "data + model + scenario + ecology" [1] - The company is developing dual-domain large models: (1) Zhuo Mu Niao (medical large model) trained on medical literature, case histories, and pharmaceutical knowledge graphs, evaluated by medical experts for enhanced professionalism and accuracy; (2) Tian Gong Yi Hao (decision-making large model) integrates diverse market data and industry logic with medical knowledge to create marketing strategies and resource allocation plans [1] Group 2: Data Resources and Industry Insights - The company possesses a diverse range of health industry data resources covering medical institutions, health check-up centers, and pharmacies, creating a comprehensive data system from hospitals to outpatient services and from prevention to treatment [1] - With 18 years of industry know-how, the company decodes the business logic behind the data and dissects complex business scenarios to assist in key decision-making [1] Group 3: AI Service System and Team Collaboration - The company has established a complete AI service system from foundational to front-end applications, capable of meeting diverse needs from SMEs to large corporate clients [2] - The team and partners combine top-tier AI technology with extensive pharmaceutical experience, ensuring the integration of technology with medical scenarios to create quantifiable value [2] Group 4: Core Scenarios for AI Implementation - The company aims to drive industry transformation by leveraging its core capabilities in four key scenarios: health industry marketing, medical services, pharmacies, and health management [2] - In marketing, the company is launching commercial AI agents based on the "Tian Gong Yi Hao" decision model for more efficient marketing strategy generation [2] - In the medical sector, the focus will be on developing the "iMDT" intelligent agent for multidisciplinary consultations to enhance decision quality for doctors and hospitals [2] - For pharmacies, the company will enhance professional service capabilities across five dimensions: operational insights, products, diseases, membership, and staff to achieve intelligent management [2] - In health management, the company is committed to developing a comprehensive "prevention-screening-intervention" health management system through a matrix of intelligent agents [2] Group 5: Future Development - The company will adhere to its established development strategy, building an efficient collaborative ecosystem of health industry intelligent agents based on industrial-level data, leading the industry into a new era of intelligence [3]

Core Viewpoint - Zhongkang Holdings (02361.HK) is transitioning from a "provider of intelligent solutions in the life sciences" to an "AI technology service company based on health industry data elements and ecological resources" [1] Group 1: AI Models - The company has developed a dual-domain large model: - Zhuomuniao (medical large model) is trained on medical literature, medical records, and pharmaceutical knowledge graphs, demonstrating enhanced professionalism and accuracy in understanding complex medical terminology and compliance requirements [2] - Tiangong No. 1 (decision-making large model) integrates diverse market data and industry logic accumulated over years, along with medical knowledge, to convert medical cognition into actionable marketing strategies and resource allocation plans, aiming to close the value loop from "medical cognition" to "business results" [2] Group 2: Data Resources and Industry Insights - The company possesses a diversified health industry data resource that covers a wide range of medical institutions, health check-up centers, and pharmacies, creating a comprehensive data system that spans from hospitals to outpatient services, online to offline, and prevention to treatment [3] - With 18 years of industry know-how, the company decodes the commercial logic behind the data and dissects complex business scenarios to assist in key decision-making [3] Group 3: AI Service System and Team Collaboration - The company has established a complete AI service system that ranges from foundational infrastructure to front-end applications, capable of meeting diverse needs from small and medium enterprises to large corporate clients [4] - The team and partners combine top-tier AI technology with extensive pharmaceutical experience, ensuring the integration of technology with medical scenarios to deliver quantifiable value [4]

Group 1 - The company, Zhongkang Holdings (02361), announced the grant of 4.4725 million share awards to grantees under its share incentive plan on January 15, 2026 [1]

Group 1 - The core point of the article is that Zhongkang Holdings (02361.HK) announced the grant of 4.4725 million share awards to grantees under its share award scheme on January 15, 2026 [1]